Rigel Pharmaceuticals Inc (NASDAQ:RIGL) 2017 Q2 Sentiment Change

November 15, 2017 - By reb123z

 Rigel Pharmaceuticals Inc (NASDAQ:RIGL)  2017 Q2 Sentiment Change

Sentiment for Rigel Pharmaceuticals Inc (NASDAQ:RIGL)

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) institutional sentiment increased to 1.59 in Q2 2017. Its up 0.37, from 1.22 in 2017Q1. The ratio has improved, as 51 active investment managers started new and increased equity positions, while 32 sold and trimmed holdings in Rigel Pharmaceuticals Inc. The active investment managers in our partner’s database reported: 105.05 million shares, up from 104.49 million shares in 2017Q1. Also, the number of active investment managers holding Rigel Pharmaceuticals Inc in their top 10 equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 4 Reduced: 28 Increased: 35 New Position: 16.

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company has market cap of $547.88 million. The Firm is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. It currently has negative earnings. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

It is down 4.56% since November 15, 2016 and is uptrending. It has underperformed by 12.14% the S&P500.

Wall Street await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to release earnings on March, 6. Analysts forecast earnings per share of $-0.14, up exactly $0.02 or 12.50 % from 2014’s $-0.16 EPS. After posting $-0.14 EPS for the previous quarter, Rigel Pharmaceuticals, Inc.’s analysts now forecast 0.00 % EPS growth.

Great Point Partners Llc holds 4.45% of its portfolio in Rigel Pharmaceuticals, Inc. for 9.11 million shares. Sio Capital Management Llc owns 1.35 million shares or 1.75% of their US portfolio. Moreover, Dafna Capital Management Llc has 0.86% invested in the company for 443,478 shares. The Massachusetts-based Cormorant Asset Management Llc has invested 0.7% in the stock. Ghost Tree Capital Llc, a New York-based fund reported 1.10 million shares.#img1#

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Ratings analysis reveals 100% of Rigel Pharmaceuticals’s analysts are positive. Out of 4 Wall Street analysts rating Rigel Pharmaceuticals, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3.25 while the high is $11. The stock’s average target of $6.45 is 72.46% above today’s ($3.74) share price. RIGL was included in 13 notes of analysts from August 8, 2015. As per Monday, May 16, the company rating was maintained by Jefferies. The stock has “Buy” rating by H.C. Wainwright on Wednesday, July 13. The rating was initiated by Piper Jaffray on Monday, June 13 with “Overweight”. The firm earned “Buy” rating on Tuesday, November 7 by BMO Capital Markets. The stock has “Buy” rating by BMO Capital Markets on Wednesday, June 7. Jefferies maintained it with “Buy” rating and $5.0 target in Monday, September 4 report. The rating was maintained by BMO Capital Markets on Monday, June 19 with “Buy”. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Outperform” rating given on Wednesday, August 31 by BMO Capital Markets. The firm has “Buy” rating given on Monday, November 6 by H.C. Wainwright. As per Monday, October 2, the company rating was maintained by BMO Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.